COPENHAGEN, Denmark I March 10, 2025 I Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise ...
EMERYVILLE, CA, USA I March 10, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...
BAGSVAERD, Denmark I March 10, 2025 I Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme.
CHENGDU, China I March 10, 2025 I Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's ...
BOTHELL, WA, USA I March 10, 2025 I Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted ...
AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment -- ...
The report covers 2024 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy ...
About the ROCKET Phase 3 Program ROCKET is a comprehensive, global Phase 3 clinical trial program comprised of eight studies intended to establish the safety and efficacy profile of rocatinlimab in ...
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm ...
PARIS, France and TARRYTOWN, NY, USA I March 8, 2025 I Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent ...
HANGZHOU, China and LONDON, UK I March 07, 2025 I MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, announces today ...
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback